| Course | NRNP 6557 Adult Acute Care: Comprehensive Patient Management II |
|---|---|
| Week | Week 7 |
| Paper type | Evidence appraisal paper |
| Length | About 1,010 words, 6 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | MSN Adult-Gerontology Acute Care Nurse Practitioner (AGACNP) |
| Updated | October 2026 |
Free sample paper for NRNP 6557 Week 7
Evidence Appraisal: Intermittent Versus Continuous Proton Pump Inhibitor After Endoscopic Hemostasis of a High-Risk Ulcer
Student Name
College of Nursing, Walden University
NRNP 6557: Adult Acute Care: Comprehensive Patient Management II
Instructor Name
Month Day, Year
Evidence Appraisal: Intermittent Versus Continuous Proton Pump Inhibitor After Endoscopic Hemostasis of a High-Risk Ulcer
The Question, Structured
The practice question arose from the patient followed through this course: a 67-year-old man with a duodenal ulcer and a nonbleeding visible vessel treated endoscopically, who was kept on a continuous pantoprazole infusion, which tied him to an intravenous pump and a step-down bed. Population: adults with peptic ulcer bleeding and high-risk stigmata (active bleeding, nonbleeding visible vessel, or adherent clot) after successful endoscopic hemostasis. Intervention: intermittent high-dose proton pump inhibitor, by intravenous bolus or by mouth. Comparison: an 80 mg intravenous bolus followed by continuous infusion at 8 mg per hour for 72 hours. Outcome: rebleeding within 7 to 30 days; secondary outcomes surgery, transfusion, and mortality.
Search and Exclusions
PubMed was searched on September 29, 2026, combining terms for intermittent or bolus dosing, continuous infusion, proton pump inhibitors by class and by name, and peptic ulcer bleeding, limited to randomized controlled trials; the search returned 30 records. Excluded: trials of bleeding after endoscopic submucosal dissection, trials of stress ulcer prophylaxis in critically ill patients, trials comparing proton pump inhibitors with H2-receptor antagonists or somatostatin, and pH studies in healthy volunteers. One systematic review with meta-analysis identified from the reference lists of the included trials was added. Five trials and one meta-analysis are appraised below.
Study by Study
Lau et al. (2000). Design: double-blind randomized trial, intravenous omeprazole bolus plus 72-hour infusion versus placebo after endoscopic therapy. Sample: 240 patients with actively bleeding ulcers or nonbleeding visible vessels, Hong Kong. Findings: recurrent bleeding within 30 days 6.7% with omeprazole versus 22.5% with placebo; most rebleeding occurred in the first 3 days. Limitation for this question: it compares infusion with nothing, so it shows that high-dose acid suppression works, not that the infusion is required. Its population, however, matches our patient closely.
Hung et al. (2007). Design: randomized trial with three arms, pantoprazole infusion, pantoprazole 40 mg intravenous bolus every 12 hours, or no acid suppression for 3 days after endoscopic hemostasis. Sample: 153 patients analyzed of 168 enrolled. Findings: rebleeding was 3.7% with infusion, 4.1% with bolus, and 16.0% with no treatment; infusion and bolus did not differ in rebleeding, transfusion, surgery, hospital stay, or gastric pH. Limitation: 15 patients excluded after enrollment; each arm around 50 patients, too few to exclude a modest difference between the two active arms. Its direct head-to-head design makes it more relevant than its size suggests.
Andriulli et al. (2008). Design: multicenter randomized trial of high-dose infusion versus a standard 40 mg daily intravenous dose for 72 hours. Sample: 474 patients with active bleeding, visible vessel, or adherent clot, Italy. Findings: rebleeding 11.8% with high dose versus 8.1% with standard dose, not significantly different. Limitation: it tests dose rather than delivery method, and the standard arm was a single daily dose, lower than any intermittent regimen a clinician would use for a high-risk ulcer. The largest trial here, but the least matched to the question.
Javid et al. (2009). Design: randomized trial of oral versus intravenous omeprazole, pantoprazole, or rabeprazole after endoscopic hemostasis, measuring 72-hour intragastric pH. Sample: 90 patients. Findings: mean 72-hour pH above 6 with every drug and route, with no significant difference between oral and intravenous administration. Limitation: pH is a surrogate outcome, not rebleeding. It supports the mechanism for intermittent and oral therapy, but cannot show a clinical outcome by itself.
Yüksel et al. (2008). Design: prospective randomized trial of intermittent versus continuous intravenous pantoprazole after endoscopic therapy, in ulcers that were bleeding actively or carried a visible vessel. Findings: rebleeding 6.1% versus 8.3%; hospital stay, transfusion, and need for surgery similar. Limitation: single center, and the published abstract reports rates without group sizes, so its precision cannot be judged from the abstract alone.
Sachar et al. (2014). Design: meta-analysis pooling randomized trials in endoscopically treated high-risk ulcers comparing intermittent proton pump inhibitor therapy with bolus plus 72-hour infusion, using a noninferiority margin of 3% set in advance. Findings: risk ratio for rebleeding within 7 days 0.72, with an absolute risk difference of -2.64% whose upper confidence boundary, -0.28%, fell well below the margin; no outcome favored the infusion. Limitation: it inherits the small size and variable quality of its component trials. It is the strongest single source for the question because it was designed to answer exactly it.
Synthesis
The body of evidence supports, with moderate confidence, that after a high-risk ulcer is treated endoscopically, giving high-dose proton pump inhibitor intermittently prevents rebleeding as well as a continuous infusion. High-dose acid suppression clearly reduces rebleeding compared with none (Lau et al., 2000; Hung et al., 2007). Head-to-head trials show no difference between intermittent and continuous delivery (Hung et al., 2007; Yüksel et al., 2008), and the meta-analysis designed for noninferiority confirms it (Sachar et al., 2014). The pH study shows that oral and intravenous routes reach the same acid suppression (Javid et al., 2009), which explains why delivery method matters less than dose. The American College of Gastroenterology guideline now accepts high-dose therapy given either continuously or intermittently for 3 days (Laine et al., 2021). Confidence is moderate rather than high because the individual trials are small, and the evidence for oral rather than intravenous intermittent dosing rests mainly on a surrogate outcome.
Applicability
The finding transfers to the adult acute population in question with two reservations. The trials enrolled patients with ulcers similar to our patient's, with active bleeding or nonbleeding visible vessels treated endoscopically, so the population matches on the feature that matters most. But few trials reported how many patients were on dual antiplatelet therapy, which raises rebleeding risk and is common in acute care patients with recent coronary stents. And most trials used intravenous boluses; switching directly to oral therapy after endoscopy is supported by pH data, not by rebleeding trials. For a patient like ours, a reasonable application is intravenous pantoprazole 40 mg every 12 hours for 72 hours in place of the infusion, allowing earlier transfer from step-down care, followed by the recommended oral twice-daily regimen.
References
Andriulli, A., Loperfido, S., Focareta, R., Leo, P., Fornari, F., Garripoli, A., Tonti, P., Peyre, S., Spadaccini, A., Marmo, R., Merla, A., Caroli, A., Forte, G. B., Belmonte, A., Aragona, G., Imperiali, G., Forte, F., Monica, F., Caruso, N., & Perri, F. (2008). High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: A multicentre, randomized study. The American Journal of Gastroenterology, 103(12), 3011-3018. https://doi.org/10.1111/j.1572-0241.2008.02149.x
Hung, W. K., Li, V. K., Chung, C. K., Ying, M. W., Loo, C. K., Liu, C. K., Lam, B. Y., & Chan, M. C. (2007). Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. ANZ Journal of Surgery, 77(8), 677-681. https://doi.org/10.1111/j.1445-2197.2007.04185.x
Javid, G., Zargar, S. A., U-Saif, R., Khan, B. A., Yatoo, G. N., Shah, A. H., Gulzar, G. M., Sodhi, J. S., & Khan, M. A. (2009). Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. Journal of Gastroenterology and Hepatology, 24(7), 1236-1243. https://doi.org/10.1111/j.1440-1746.2009.05900.x
Laine, L., Barkun, A. N., Saltzman, J. R., Martel, M., & Leontiadis, G. I. (2021). ACG clinical guideline: Upper gastrointestinal and ulcer bleeding. The American Journal of Gastroenterology, 116(5), 899-917. https://doi.org/10.14309/ajg.0000000000001245
Lau, J. Y., Sung, J. J., Lee, K. K., Yung, M. Y., Wong, S. K., Wu, J. C., Chan, F. K., Ng, E. K., You, J. H., Lee, C. W., Chan, A. C., & Chung, S. C. (2000). Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. The New England Journal of Medicine, 343(5), 310-316. https://doi.org/10.1056/NEJM200008033430501
Sachar, H., Vaidya, K., & Laine, L. (2014). Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: A systematic review and meta-analysis. JAMA Internal Medicine, 174(11), 1755-1762. https://doi.org/10.1001/jamainternmed.2014.4056
Yüksel, I., Ataseven, H., Köklü, S., Ertuğrul, I., Başar, O., Odemiş, B., Ibiş, M., Saşmaz, N., & Sahin, B. (2008). Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: A prospective randomized study. Digestion, 78(1), 39-43. https://doi.org/10.1159/000158227
The Walden NRNP 6557 Week 7 instructions
The seventh week of NRNP 6557 typically asks for an evidence appraisal on a practice question from the ongoing case. You structure the question, describe your search, appraise each study's strengths and limits, synthesize, and decide how the evidence applies to the patient. Faculty penalize summary without appraisal. Cite each study in APA 7. Three to six studies or one strong meta-analysis plus trials is common. A recommendation is usually expected. The practice question should be one that could change care. NRNP 6557 faculty want the practice question written in PICO form. Describe where and how you searched. Appraise each study for design, population and bias. End with a recommendation tied to the patient. Include the guideline's position.
How the NRNP 6557 Week 7 example is put together
The appraisal opens with the practice stated as a question in structured form, population, intervention, comparison and outcome laid out so the search that follows has boundaries. A short methods passage records where the search ran and what was excluded, which is what makes the result checkable. Then five to eight studies are appraised, each with design, sample, findings and the specific weakness that limits it, and the appraisal treats a large trial with a mismatched population as less useful than a smaller one that fits. A synthesis paragraph states what the body of evidence supports and how confidently. The last section asks whether the finding transfers to the adult acute population in question, running on population characteristics rather than on anyone in particular.
NRNP 6557 Week 7 rubric: what earns full marks
Summarizing is the failure this assignment is designed to catch. A paper reporting what each study found, without saying what limits it, has described the evidence rather than appraised it, and it usually reads well while scoring badly. The second loss sits in synthesis: studies appraised individually and then never brought together leave a reader to do the integration. Third, applicability is often skipped entirely or reduced to a sentence saying more research is needed, when the rubric wants a judgment about these patients. Levels of evidence quoted as a ranking, with no discussion of quality inside the level, count for little. Old sources on a practice with recent guidance cost points quickly, as does a search section too vague to repeat.
NRNP 6557 Week 7 help: mistakes that cost marks
Appraisals lose credit when they report what each study found without saying what limits it. Appraise each one. Another common gap is ignoring the search method, so nobody can tell which studies were left out. Describe it. Writers also skip applicability, though the patient's features may differ from trial populations. Compare them. Avoid treating a meta-analysis as automatically conclusive. Note its included trials. Close with a clear recommendation for this patient. Check that the guideline year matches your citation. Writers also forget to say how the trial patients compare with the course patient, such as kidney disease. Compare them. Another frequent slip is reporting relative risks without absolute numbers. Add both. Keep citations complete. Close with what changes for him tomorrow.
Get a NRNP 6557 Week 7 example written to your instructions
Send the Week 7 prompt, the appraisal table your classroom uses and the rubric, and an example comes back filled out on a practice of comparable scope. The first one is free and arrives within 24 to 48 hours. Nothing we write draws on your clinical site, your patients or any record you are keeping there.
More NRNP 6557 papers and AGACNP samples
- NRNP 6557 Week 1: Discussion Post
- NRNP 6557 Week 2: Problem List
- NRNP 6557 Week 3: Case Management Paper
- NRNP 6557 Week 4: Discussion Post
- NRNP 6557 Week 5: Medication Reconciliation
- NRNP 6557 Week 6: Complex Case Analysis
- NRNP 6557 Week 8: Discussion post
- NRNP 6557 Week 9: Care transition plan
- NRNP 6557 Week 10: Case presentation
- NRNP 6557 Week 11: Reflection
- NRNP 6559 Week 7: Preconception counseling focused note
- NRNP 6549 Week 7: Acne and Abdominal Pain Notes
- NRNP 6566 Week 7: Acute kidney injury workup
- NRNP 6547 Week 7: Case Analysis
NRNP 6557 Week 7 questions, answered
Which practice makes a good subject?
Something done constantly and justified rarely. Routines around monitoring intervals, positioning, line care and timing tend to have thinner evidence behind them than their frequency suggests, which gives the appraisal something to find. A practice with strong recent guidance produces a short paper and a dull one, since the appraisal ends up agreeing with the guideline in every section.
How many studies should be appraised?
The sample uses six, which is enough to synthesize and few enough to appraise properly. No official number exists and your prompt may set one. Where a section asks for more, the individual entries compress and the synthesis grows, because a paper with twelve shallow appraisals and no integration scores below one with six that were actually weighed.
Does an appraisal need a recommendation?
Usually, and the sample ends with one that is conditional rather than absolute. It states what the evidence supports for this population, what it does not settle, and which patient characteristics would change the answer. Recommendations written as certainties tend to overstate what a small body of evidence can carry, and rubric language about critical judgment reads for that restraint.
Where can I find a free NRNP 6557 Week 7 sample paper?
The intermittent versus continuous PPI appraisal is printed here with the PICO question, the search, study-by-study appraisal, synthesis and applicability.
Is intermittent PPI as good as continuous after ulcer hemostasis in NRNP 6557 Week 7?
The evidence appraised suggests intermittent high-dose dosing is not inferior, so the example recommends switching the patient off the pump.